Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer

A matched subset analysis

J. Sylvester, J. C. Blasko, P. D. Grimm, R. Meier, W. Cavanagh, Mark Garzotto, J. Moul, W. Fair

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background and Purpose: In order to evaluate the effect of short-term androgen blockade on biochemical control rates for high-risk patients receiving a combination regimen of external-beam radiation therapy and low-dose-rate permanent seed implant brachytherapy, a retrospective matched subset analysis was performed. Patients and Methods: Inclusion in the high-risk cohort required at least two of the following poor prognostic factors: serum prostate specific antigen (PSA) concentration ≥10.0 ng/mL, Gleason score ≥7, or clinical stage T(2c) or T(3a) disease. Twenty-one patients who underwent androgen ablation between June 1991 and December 1995 in addition to combined-modality radiation therapy qualified as high risk, as did 77 patients who underwent combined-radiation therapy only. There was no statistically significant difference between the two groups in terms of follow-up (mean 44.6 v 47.8 months, respectively), pretreatment PSA, clinical stage, biopsy Gleason score, or the presence of all three poor prognostic factors. Results: The overall rates of freedom from biochemical failure at 5 years were 77% in the hormonally treated group and 58% in the nonhormonally treated group. The difference was not statistically significant by log rank test (P = 0.08). Conclusion: Longer follow-up with larger patient numbers is needed to define the role of adjuvant androgen ablation combined with radiation therapy.

Original languageEnglish (US)
Pages (from-to)155-159+161
JournalMolecular Urology
Volume4
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Brachytherapy
Androgens
Prostatic Neoplasms
Radiotherapy
Neoplasm Grading
Prostate-Specific Antigen
Combined Modality Therapy
Seeds
Biopsy
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer : A matched subset analysis. / Sylvester, J.; Blasko, J. C.; Grimm, P. D.; Meier, R.; Cavanagh, W.; Garzotto, Mark; Moul, J.; Fair, W.

In: Molecular Urology, Vol. 4, No. 3, 2000, p. 155-159+161.

Research output: Contribution to journalArticle

Sylvester, J. ; Blasko, J. C. ; Grimm, P. D. ; Meier, R. ; Cavanagh, W. ; Garzotto, Mark ; Moul, J. ; Fair, W. / Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer : A matched subset analysis. In: Molecular Urology. 2000 ; Vol. 4, No. 3. pp. 155-159+161.
@article{34875f6cae074a608a3c588111ec2f69,
title = "Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: A matched subset analysis",
abstract = "Background and Purpose: In order to evaluate the effect of short-term androgen blockade on biochemical control rates for high-risk patients receiving a combination regimen of external-beam radiation therapy and low-dose-rate permanent seed implant brachytherapy, a retrospective matched subset analysis was performed. Patients and Methods: Inclusion in the high-risk cohort required at least two of the following poor prognostic factors: serum prostate specific antigen (PSA) concentration ≥10.0 ng/mL, Gleason score ≥7, or clinical stage T(2c) or T(3a) disease. Twenty-one patients who underwent androgen ablation between June 1991 and December 1995 in addition to combined-modality radiation therapy qualified as high risk, as did 77 patients who underwent combined-radiation therapy only. There was no statistically significant difference between the two groups in terms of follow-up (mean 44.6 v 47.8 months, respectively), pretreatment PSA, clinical stage, biopsy Gleason score, or the presence of all three poor prognostic factors. Results: The overall rates of freedom from biochemical failure at 5 years were 77{\%} in the hormonally treated group and 58{\%} in the nonhormonally treated group. The difference was not statistically significant by log rank test (P = 0.08). Conclusion: Longer follow-up with larger patient numbers is needed to define the role of adjuvant androgen ablation combined with radiation therapy.",
author = "J. Sylvester and Blasko, {J. C.} and Grimm, {P. D.} and R. Meier and W. Cavanagh and Mark Garzotto and J. Moul and W. Fair",
year = "2000",
language = "English (US)",
volume = "4",
pages = "155--159+161",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer

T2 - A matched subset analysis

AU - Sylvester, J.

AU - Blasko, J. C.

AU - Grimm, P. D.

AU - Meier, R.

AU - Cavanagh, W.

AU - Garzotto, Mark

AU - Moul, J.

AU - Fair, W.

PY - 2000

Y1 - 2000

N2 - Background and Purpose: In order to evaluate the effect of short-term androgen blockade on biochemical control rates for high-risk patients receiving a combination regimen of external-beam radiation therapy and low-dose-rate permanent seed implant brachytherapy, a retrospective matched subset analysis was performed. Patients and Methods: Inclusion in the high-risk cohort required at least two of the following poor prognostic factors: serum prostate specific antigen (PSA) concentration ≥10.0 ng/mL, Gleason score ≥7, or clinical stage T(2c) or T(3a) disease. Twenty-one patients who underwent androgen ablation between June 1991 and December 1995 in addition to combined-modality radiation therapy qualified as high risk, as did 77 patients who underwent combined-radiation therapy only. There was no statistically significant difference between the two groups in terms of follow-up (mean 44.6 v 47.8 months, respectively), pretreatment PSA, clinical stage, biopsy Gleason score, or the presence of all three poor prognostic factors. Results: The overall rates of freedom from biochemical failure at 5 years were 77% in the hormonally treated group and 58% in the nonhormonally treated group. The difference was not statistically significant by log rank test (P = 0.08). Conclusion: Longer follow-up with larger patient numbers is needed to define the role of adjuvant androgen ablation combined with radiation therapy.

AB - Background and Purpose: In order to evaluate the effect of short-term androgen blockade on biochemical control rates for high-risk patients receiving a combination regimen of external-beam radiation therapy and low-dose-rate permanent seed implant brachytherapy, a retrospective matched subset analysis was performed. Patients and Methods: Inclusion in the high-risk cohort required at least two of the following poor prognostic factors: serum prostate specific antigen (PSA) concentration ≥10.0 ng/mL, Gleason score ≥7, or clinical stage T(2c) or T(3a) disease. Twenty-one patients who underwent androgen ablation between June 1991 and December 1995 in addition to combined-modality radiation therapy qualified as high risk, as did 77 patients who underwent combined-radiation therapy only. There was no statistically significant difference between the two groups in terms of follow-up (mean 44.6 v 47.8 months, respectively), pretreatment PSA, clinical stage, biopsy Gleason score, or the presence of all three poor prognostic factors. Results: The overall rates of freedom from biochemical failure at 5 years were 77% in the hormonally treated group and 58% in the nonhormonally treated group. The difference was not statistically significant by log rank test (P = 0.08). Conclusion: Longer follow-up with larger patient numbers is needed to define the role of adjuvant androgen ablation combined with radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033755608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033755608&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 155-159+161

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 3

ER -